Telemedicine in the Time of the COVID-19 Pandemic: Results from the First Survey among Italian Pediatric Diabetes Centers.
Telemedicine in the Time of the COVID-19 Pandemic: Results from the First Survey among Italian Pediatric Diabetes Centers.
复制标题
远程医疗在COVID-19大流行时期：意大利小儿糖尿病中心的第一次调查结果。
DOI：
10.3390/healthcare9070815
复制
发表时间：
2021-06-28
期刊：
影响因子：
--
通讯作者：
The Diabetes Study Group Of The Italian Society For Pediatric Endocrinology
中科院分区：
文献类型：
--
作者：
Tornese G;Schiaffini R;Mozzillo E;Franceschi R;Frongia AP;Scaramuzza A;On Behalf Of Hcl Expert Pathway Pediatric Group;The Diabetes Study Group Of The Italian Society For Pediatric Endocrinology
背景：调查了COVID-19大流行初期1型糖尿病儿童和青少年远程医疗的使用情况。方法：邀请68家意大利儿科糖尿病中心完成一项关于其儿科患者远程医疗使用情况的调查，将其分为无技术组（每日多次注射和自我监测血糖）和技术组（胰岛素泵和/或快速或连续血糖监测）。结果：60.3%的中心完成了调查。在无技术组和有技术组中，最常用的沟通方式是通用下载门户、与个人医生手机的即时通讯、工作电子邮件和打电话给医生的手机，除了电子邮件的使用在无技术组中更高（p = 0.03），没有差异。74%的中心没有任何系统化和/或报销，地区间差异显著（p = 0.03）。结论：几乎所有意大利儿童糖尿病中心都以半自愿的方式使用远程医疗，缺乏适当的法规、报销制度、法律可追溯性和认证制度。
Background: Use of telemedicine for children and adolescents with type 1 diabetes at the beginning of the COVID-19 pandemic was investigated. Method: 68 Italian pediatric diabetes centers were invited to complete a survey about telemedicine usage in their pediatric patients, allocated to the no-tech group (multiple daily injections and self-monitoring blood glucose) and the tech group (insulin pump and/or flash- or continuous-glucose monitoring). Results: 60.3% of the centers completed the survey. In both the no-tech and tech groups, the most used ways of communication were generic download portals, instant messaging with personal physicians’ mobiles, working emails, and phone calls to physicians’ mobiles, with no difference, except for the use of email being higher in the no-tech group (p = 0.03). Seventy-four percent of the centers did not have any systematization and/or reimbursement, with significant differences among regions (p = 0.03). Conclusions: Almost all Italian pediatric diabetes centers use telemedicine in a semi-volunteering manner, lacking proper codification, reimbursement system, legal traceability, and accreditation system.
登录
查看更多内容
影响因子：
3.6
作者：
Ferorelli D;Nardelli L;Spagnolo L;Corradi S;Silvestre M;Misceo F;Marrone M;Zotti F;Mandarelli G;Solarino B;Dell'Erba A
通讯作者：
Dell'Erba A
影响因子：
5.2
作者：
Strehle, E. M.;Shabde, N.
通讯作者：
Shabde, N.
影响因子：
5.6
作者：
Lee SWH;Ooi L;Lai YK
通讯作者：
Lai YK
影响因子：
3.6
作者：
Giorgetti C;Ferrito L;Zallocco F;Iannilli A;Cherubini V;Study Group for Diabetes of ISPED
通讯作者：
Study Group for Diabetes of ISPED